BO1 Stock Chart & Stats
€8.44
€0.11(1.30%)
At close: 4:00 PM EDT
€8.44
€0.11(1.30%)
Day’s Range― - ―
52-Week Range€5.18 - €10.19
Previous CloseN/A
Volume0.00
Average Volume (3M)83.00
Market Cap
€1.98B
Enterprise Value€2.93K
Total Cash (Recent Filing)€239.25M
Total Debt (Recent Filing)€858.08M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 05, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding254,162,660
10 Day Avg. Volume0
30 Day Avg. Volume83
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-13.74
Price to Sales (P/S)1.87
P/FCF Ratio5.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.97Price Target Upside124.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.23
Revenue Forecast (FY)€586.39M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationMaterial positive cash generation is durable: TTM operating cash flow (~$296M) and FCF (~$294M) fund operations, cover accounting losses (operating cash flow to net income ~1.52x), and reduce near-term external financing need, supporting execution of launches and pivotal trials.
Meaningful Debt ReductionSharp deleveraging materially lowers interest and refinancing risk, improving financial resilience. With debt now minimal versus recent peaks, the company has more flexibility to allocate cash to commercialization, milestones, or targeted external R&D without heavy near-term fixed-charge constraints.
Commercial Momentum, Licensing And Pipeline ProgressConsistent ORLADEYO growth and maintained guidance create a predictable revenue base to fund pipeline. The European navenibart license (upfront, milestones, royalties) de-risks regional commercialization and boosts liquidity, while Phase 3 enrollment and early efficacy data strengthen long-term product optionality.
Bears Say
Persistent Negative Shareholders' EquityNegative equity is a structural capital-structure weakness that constrains financial flexibility, complicates covenant metrics and access to equity markets, and makes the company more reliant on cash generation or dilutive financing to fund growth or unexpected needs over the medium term.
Acquisition Charge, Dilution And Added FinancingThe large GAAP in‑process R&D charge materially impaired reported earnings and reflects acquisition accounting; share issuance dilutes existing holders and the new credit facility raises leverage and contractual obligations, increasing financing costs and integration funding needs over coming quarters.
Competitive Pressure & Pediatric Manufacturing UncertaintyA manufacturing delay for pediatric pellets introduces timing risk for converting free-to-paid demand, while new injectable entrants and rival therapies structurally raise retention and switching risks in HAE; together they pressure long-term market share and revenue durability.
BioCryst News
BO1 FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was €5.18 and its highest was €10.19 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is €1.98B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on May 06, 2026. The company reported -€2.583 earnings per share for the quarter, missing the consensus estimate of €0.038 by -€2.621.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is 0.13.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 254,162,660 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of -€2.583 in its last earnings report, missing expectations of €0.038. Following the earnings report the stock price went down -8.446%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:BO1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.97 (124.80% Upside)
€18.97 (124.80% Upside)
Blogger Sentiment
Bullish
DE:BO1 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €86.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.12%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BO1 Company Deck
BO1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and progressing late-stage and early-stage pipeline programs, with double-digit revenue and operating profit growth on a non-GAAP basis, meaningful licensing and financing activity that bolsters liquidity, and positive clinical momentum for navenibart and BCX17725. Key negatives include a manufacturing delay for the pediatric pellet fulfillment (timing uncertain), a large GAAP in-process R&D charge of $698M from the Astria acquisition, increased R&D spend and financing/dilution to fund the deal, and ongoing competitive entrants in the HAE market. Management maintained 2026 guidance and emphasized confidence in ORLADEYO demand and pipeline execution.View all DE:BO1 earnings summariesBO1 Stock 12 Month Forecast
Average Price Target
€18.97
▲(124.80% Upside)